Several analysts have recently updated their ratings and price targets for Icon (NASDAQ: ICLR):

  • 1/10/2018 – Icon was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 1/9/2018 – Icon was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $132.00 price target on the stock. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 1/3/2018 – Icon was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. They now have a $128.00 price target on the stock. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 12/31/2017 – Icon was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 12/27/2017 – Icon was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $127.00 price target on the stock. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 11/13/2017 – Icon had its “overweight” rating reaffirmed by analysts at KeyCorp. They now have a $125.00 price target on the stock, up previously from $115.00. They noted that the move was a valuation call. They noted that the move was a valuation call.

Icon Plc (NASDAQ ICLR) opened at $117.81 on Thursday. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. The firm has a market cap of $6,370.00, a PE ratio of 22.88, a price-to-earnings-growth ratio of 1.63 and a beta of 0.61. Icon Plc has a 1 year low of $76.46 and a 1 year high of $124.48.

Icon (NASDAQ:ICLR) last issued its earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.32 by $0.03. Icon had a net margin of 16.37% and a return on equity of 28.42%. The firm had revenue of $440.30 million during the quarter, compared to analyst estimates of $438.09 million. During the same quarter last year, the business earned $1.19 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. sell-side analysts expect that Icon Plc will post 5.37 EPS for the current fiscal year.

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.